Results 261 to 270 of about 447,676 (302)
Some of the next articles are maybe not open access.
Growth Hormone Therapy and Malignancy
Hormone Research, 1997The possibility that human growth hormone (GH) replacement therapy might either increase the risk of cancer recurrence in a child who has previously been treated for a brain tumour or leukaemia, or induce de novo cancer, has worried paediatricians for a number of years.
S M, Shalet +2 more
openaire +2 more sources
American family physician, 1990
Growth hormone from human pituitary glands has been available for 30 years. Because of the scarce supply and the danger of transmitting Creutzfeldt-Jakob disease, use of the hormone was discontinued in 1984. Fortunately, synthetic growth hormone produced with recombinant DNA technology became available in 1985 and eliminated the risk of Creutzfeldt ...
L, Shulman, J L, Miller, L I, Rose
openaire +1 more source
Growth hormone from human pituitary glands has been available for 30 years. Because of the scarce supply and the danger of transmitting Creutzfeldt-Jakob disease, use of the hormone was discontinued in 1984. Fortunately, synthetic growth hormone produced with recombinant DNA technology became available in 1985 and eliminated the risk of Creutzfeldt ...
L, Shulman, J L, Miller, L I, Rose
openaire +1 more source
Growth Hormone Therapy in Adults
Annual Review of Medicine, 2003Growth hormone (GH) is classically linked with linear growth in childhood but continues to have important metabolic actions throughout life. GH deficiency in adulthood causes a distinct syndrome with significant morbidities. These include increased total and visceral fat, decreased muscle mass and aerobic capacity, affective disturbances, abnormal ...
David E, Cummings, George R, Merriam
openaire +2 more sources
Growth hormone therapy and leukaemia
European Journal of Pediatrics, 1989Following an initial report from Japan in 1987, 15 growth hormone (GH)-deficient patients developed leukaemia during or following GH treatment. Nearly all available pituitary and biosynthetic growth hormones have been used. In 14 of these 15 patients GH treatment was initiated in 1975 or later with doses between 4.5 and 18IU/m2 per week.
N, Stahnke, H J, Zeisel
openaire +2 more sources
Growth and Growth Hormone Therapy in Hypochondroplasia
Acta Paediatrica, 1990ABSTRACT. The growth of 84 patients with hypochondroplasia (56 male, 28 female) was studied. A wide spectrum of severity was found from quite severe short limbed dwarfism to short apparently normal prepubertal children who manifested disproportion only at puberty when growth failed.
S, Appan +4 more
openaire +2 more sources
Individualization of growth hormone therapy
Best Practice & Research Clinical Endocrinology & Metabolism, 2008Short children born small for gestational age account for 20% of patients with short stature. These children should be investigated individually to identify treatable causes of their short stature and any associated neurodevelopmental problems. Randomized controlled growth hormone therapy trials demonstrate growth acceleration in childhood and improved
openaire +2 more sources
Florence
Summary: The growth of the organism is not influenced by growth hormone only; the influencing factors are nutrition, genetic predisposition, chronic diseases, the course of pregnancy, the birth itself and other hormonal factors – thyroid hormones, sex hormones, or adrenal hormones.
openaire +1 more source
Summary: The growth of the organism is not influenced by growth hormone only; the influencing factors are nutrition, genetic predisposition, chronic diseases, the course of pregnancy, the birth itself and other hormonal factors – thyroid hormones, sex hormones, or adrenal hormones.
openaire +1 more source
Growth Hormone Therapy in Heart Failure
Heart Failure Clinics, 2018Several studies have shown that growth hormone (GH) deficiency is common in chronic heart failure and is associated with impaired functional capacity and poor outcomes. Data derived from animal models showed beneficial effects of GH treatment on peripheral vascular resistance, cardiac function, and survival.
Salzano, Andrea +6 more
openaire +3 more sources
Prepubertal gynecomastia during growth hormone therapy
The Journal of Pediatrics, 1995We report 22 cases of prepubertal gynecomastia diagnosed during growth hormone (GH) treatment. The age and dose range were 2 to 12 years and 0.18 [corrected] to 0.3 mg/kg per week, respectively. In most of the patients, gynecomastia appeared between 0.5 and 7 months after GH was started. Three boys were using drugs other than GH. This condition appears
S, Malozowski, B V, Stadel
openaire +2 more sources
Growth failure and hormone therapy
British Journal of Nursing, 2014One of the causes of growth failure is growth hormone deficiency. The outcome of growth hormone therapy to treat this depends on a number of multifaceted issues, including the child, the family and the choice of medication device. Providing support and promoting adherence—key nurse roles—are essential for success
openaire +2 more sources